INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
January 11, 2024 16:32 ET
|
Nanobiotix S.A.
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 11 janv. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext...
Voting Rights and Shares Capital of the Company
January 11, 2024 16:32 ET
|
Nanobiotix S.A.
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 11,...
LianBio Transfere Ses Droits De Développement Et De Commercialisation De NBTXR3 En Chine Et Dans D’autres Marchés Asiatiques
December 26, 2023 02:00 ET
|
Nanobiotix S.A.
PARIS et CAMBRIDGE, Mass., 26 déc. 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – la « Société »), société française de biotechnologie en phase de développement clinique...
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
December 26, 2023 02:00 ET
|
Nanobiotix S.A.
PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based...
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
December 13, 2023 16:15 ET
|
Nanobiotix S.A.
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 déc. 2023 (GLOBE NEWSWIRE) -- Place de cotation :...
Voting Rights and Shares Capital of the Company
December 13, 2023 16:15 ET
|
Nanobiotix S.A.
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 13,...
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
December 04, 2023 16:22 ET
|
Nanobiotix S.A.
Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately...
NANOBIOTIX ANNONCE LA CLÔTURE DE L'INVESTISSEMENT RESTANT DE 4,8 MILLIONS DE DOLLARS DE JOHNSON & JOHNSON INNOVATION - JJDC, INC.
December 04, 2023 16:16 ET
|
Nanobiotix S.A.
Le produit brut total d'environ 50,9 millions d'euros (équivalent à environ 53,8 millions de dollars) reçu par NANOBIOTIX a augmenté pour être à 55,5 millions d'euros environ (équivalent à environ...
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
December 04, 2023 16:16 ET
|
Nanobiotix S.A.
Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately...
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
November 13, 2023 16:15 ET
|
Nanobiotix S.A.
$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR316.9 months median progression free survival (mPFS) and 23.1...